InsidersTradesSigma
ABIVAX Stock: price and management transactions · France · AMF
Follow the ABIVAX stock price and the full directors' dealings record of the company, a listed equity based in France. Shares trade on FR FR, under the oversight of AMF. Operating in the Healthcare & Pharma sector, ABIVAX has logged 64 reports. Market capitalisation: €10.8bn. The latest transaction was reported on 29 June 2026 (Acquisition). Among the most active insiders: marc de garidel thoron. Every trade is openly available.
64
Insider Decl.
0
Thresholds
€10m
8 ops.
Buy Volume
€282m
21 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate ABIVAX Buy (bullish), based on 6 analysts. Average price target: €130.06.
46Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 29 June 2026
Declarations64 total
17,728 shares0ActionEuronext Paris2026DD1123383
Ideal exit: 23 Mar 2027 (T+270)
35,456 shares0ActionEuronext Paris2026DD1116477
Ideal exit: 15 Feb 2027 (T+270)
35,456 shares0ActionEuronext Paris2026DD1102067
Ideal exit: 14 Dec 2026 (T+270)
2,471 shares@ €20.2350.0% of flowWarrants BSA 2026/1Euronext Paris2026DD1095725
7,661 shares@ €20.2375.6% of flowBSA 2026-1Euronext Paris2026DD1095418
217,728 shares0ActionEuronext Paris2026DD1092212
Ideal exit: 29 Oct 2026 (T+270)
950,000 shares@ US$122.407939.2% of flowAmerican Depositary SharesNasdaq Global Market (US)2026DD1089198
17,728 shares0ActionEuronext Paris2025DD1074474
Ideal exit: 7 Sept 2026 (T+270)
16,400 shares@ €11.5779.1% of flowwarrantsEuronext Paris2025DD1072558
35,456 shares0ActionEuronext Paris2025DD1070453
Ideal exit: 10 Aug 2026 (T+270)
590,877 shares@ €94.16418.8% of flowAmerican Depositary SharesNasdaq Global Market2025DD1066576
590,877 shares@ US$94.16418.8% of flowAmerican Depositary SharesNasdaq Global Market2025DD1066880
17,728 shares0ActionEuronext Paris2025DD1062687
17,728 shares0ActionEuronext Paris2025DD1056809
1,104,640 shares@ €15.087921.8% of flowActionEuronext Paris2025DD1053421
1,104,640 shares@ €54.0078.2% of flowActionEuronext Paris2025DD1053431
17,728 shares0ActionEuronext Paris2025DD1051889
270,000 shares@ US$64.005.8% of flowAmerican Depositary SharesNasdaq Global Market2025DD1050946
17,728 shares0ActionEuronext Paris2025DD1044615
Ideal exit: 21 Mar 2026 (T+270)
17,728 shares0ActionHors plateforme de négociation2025DD1040533
Ideal exit: 22 Feb 2026 (T+270)
39,370 shares@ €1.2750.0% of flowWarrants BSA 2025Euronext Paris2025DD1036451
17,738 shares0ActionEuronext Paris2025DD1033805
35,456 shares0ActionEuronext Paris2025DD1027190
Ideal exit: 15 Dec 2025 (T+270)
17,728 shares0ActionEuronext Paris2025DD1019890
Ideal exit: 3 Nov 2025 (T+270)
25 of 64 declarations
About ABIVAX
Abivax SA is a French clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases. Founded in Paris in 2013, the company has gradually established itself as a visible European biotech player by building its strategy around immune-regulatory mechanisms inspired by the body’s natural biology. Abivax has been listed on Euronext Paris since June 26, 2015 and has also traded on the Nasdaq Global Market since October 2023, giving it exposure to both European and U.S. capital markets. Its ISIN is FR0012333284. The company’s business is centered on the development of its lead asset, obefazimod, an orally administered modulator of microRNA-124 (miR-124). This candidate is primarily being advanced in ulcerative colitis, a chronic inflammatory bowel disease, with the goal of offering a differentiated therapeutic option for patients who remain inadequately controlled by existing treatments. Abivax positions obefazimod as the cornerstone of its pipeline, with phase 3 clinical data readouts representing key value-creation catalysts. The company has also highlighted a proprietary chemical library that may provide additional long-term development opportunities. Historically, Abivax initially built its scientific platform around immunology and antiviral approaches, before sharpening its focus on chronic inflammatory diseases. This strategic shift reflects management’s intent to concentrate resources on programs with the highest clinical and commercial potential. Today, Abivax remains primarily a research and development company, with its economic model depending on clinical progress, possible strategic partnerships, and, ultimately, commercialization of approved products. Abivax has an international footprint, with activities and teams in France and the United States to support clinical trials, investor relations, and regulatory development. Its profile was further strengthened by inclusion in the Nasdaq Biotechnology Index in December 2025, underscoring growing recognition within the global biotech ecosystem. As a growth-stage biotechnology issuer, Abivax combines advanced science, significant clinical risk, and substantial upside potential if its lead program successfully reaches the market.
